Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease
Autore:
Clark, WS; Street, JS; Feldman, PD; Breier, A;
Indirizzi:
Lilly Res Labs, Indianapolis, IN 46285 USA Lilly Res Labs Indianapolis INUSA 46285 Labs, Indianapolis, IN 46285 USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHIATRY
fascicolo: 1, volume: 62, anno: 2001,
pagine: 34 - 40
SICI:
0160-6689(200101)62:1<34:TEOOIR>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
DOUBLE-BLIND; DEMENTIA; PLACEBO; SCHIZOPHRENIA; TRIAL; HALLUCINATIONS; RISPERIDONE; HALOPERIDOL; DEPRESSION; DELUSIONS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
40
Recensione:
Indirizzi per estratti:
Indirizzo: Clark, WS Lilly Res Labs, Indianapolis, IN 46285 USA Lilly Res Labs Indianapolis IN USA 46285 anapolis, IN 46285 USA
Citazione:
W.S. Clark et al., "The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease", J CLIN PSY, 62(1), 2001, pp. 34-40

Abstract

Background: Elderly patients with Alzheimer's disease (AD) commonly exhibit psychotic symptoms, prompting clinicians to administer antipsychotics. This article compares the effects of olanzapine and placebo in the emergence of hallucinations or delusions in AD patients with symptoms of agitation/aggression but little or no psychotic symptomatology at baseline. Method: A multicenter, double-blind, placebo-controlled study was conducted in nursing home patients with AD according to DSM-IV criteria and symptoms of agitation/agression and/or psychosis. Patients (N = 206) were randomlyassigned to receive either placebo or fixed-dose olanzapine (5, 10, or 15 mg/day) for up to 6 weeks. This article analyzes data from a subgroup of patients (N = 165) with no or minimal delusions and/or hallucinations at baseline as measured by the Neuropsychiatric Inventory Nursing Home Version (NPI/NH). Three subsets of patients were identified on the basis of their symptoms at baseline: those with no clinically significant hallucinations, those with no clinically significant delusions, and those with no clinically significant delusions or hallucinations. Results: Of the patients without hallucinations or delusions at baseline (N = 75), the placebo-treated patients showed significantly greater development of these symptoms compared with olanzapine-treated patients overall (NPI/NH hallucinations + delusions mean change score, +2.73 vs. +0.27, p = .006). Similarly, of the patients without baseline hallucinations (N = 153), the placebo-treated patients showed greater hallucinations score increases than did olanzapine-treated patients overall (+1.25 vs. +0.33, p = .026), whereas patients without baseline delusions (N = 87) showed no significant treatment effects. Olanzapine had a favorable safety profile in each patient subset. Conclusion: These results suggest that, overall, olanzapine effectively attenuated emergence of psychosis in a short-term trial of patients with alzheimer's disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 04:05:10